Welcome to our dedicated page for DiagnaMed Holdings news (Ticker: DGNMF), a resource for investors and traders seeking the latest updates and insights on DiagnaMed Holdings stock.
DiagnaMed Holdings Corp. (CSE: DMED, OTCQB: DGNMF) issues frequent news updates about its activities as a Canadian technology company focused on advanced natural hydrogen extraction technologies and clean tech applications. Its announcements highlight exploration programs, project acquisitions, community partnerships, and corporate developments linked to the natural hydrogen sector.
Recent news releases describe DiagnaMed’s work in the Ontario-Québec hydrogen corridor, including soil-gas surveys in the Témiscamingue/Timiskaming Graben conducted with Québec Innovative Materials Corp. (QIMC) and the Institut National de la Recherche Scientifique (INRS). These updates report hydrogen anomalies, extensions of a natural hydrogen system, and the use of a geological exploration model that the Company associates with natural hydrogen generation and migration.
Other disclosures cover the Company’s acquisition agreement for the Colchester East Natural Hydrogen Project in Nova Scotia, which DiagnaMed states consists of 30 licenses totaling 2,104 claims. News items also discuss a Memorandum of Understanding with the Témiscamingue First Nation and QIMC to advance natural hydrogen development along the Ontario-Québec hydrogen corridor, emphasizing environmental stewardship, Indigenous participation, and community engagement.
In addition, DiagnaMed’s news flow includes governance and capital markets updates, such as leadership appointments, equity incentive grants, and the engagement of a market-making firm. Investors and observers can use the DiagnaMed news feed on Stock Titan to follow exploration milestones, partnership announcements, and strategic steps the Company reports as it advances its natural hydrogen and clean tech initiatives.
DiagnaMed Holdings Corp. is set to commercialize its BRAIN AGE® Brain Health AI Platform, an innovative solution that estimates brain age and provides a brain health score.
This platform aims to target the global digital brain health market, projected to reach USD 405.53 billion by 2031. BRAIN AGE® assesses brain health using a low-cost EEG headset and a proprietary machine-learning model, making it accessible and affordable for large-scale use.
The platform is clinically validated through studies at Drexel University and the University of Miami, showing its potential in detecting cognitive decline and optimizing brain performance.
BRAIN AGE® targets diverse users, including healthy individuals, athletes, and neurodegenerative patients, with potential applications in up to 10,000 North American clinics. The platform's goal is to empower individuals and healthcare professionals to improve brain health through personalized diagnostics and interventions.
FAQ
What is the current stock price of DiagnaMed Holdings (DGNMF)?
What is the market cap of DiagnaMed Holdings (DGNMF)?
